Search

This update reports on one of the ECDC multi-country studies that is centred around the hospital setting and severe disease, with the aim of assessing vaccine effectiveness against severe acuterespiratory infection (SARI) due to laboratory-confirmed SARS-CoV-2 within the ECDC VaccineEffectiveness, Burden and Impact Studies infrastructure (VEBIS) [1,2].

This report provides an updated overview on the progress of national COVID-19 vaccination strategies and deployment in European Union/European Economic Area (EU/EEA) countries, including updates on overall vaccine uptake and uptake by target group and vaccination strategies and policies.

This protocol presents a common methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating EU/EEA Member States.

This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.

This document reports on one of ECDC’s multi-country studies in the hospital setting to measure product-specific COVID-19 VE against any laboratory-confirmed SARS-CoV-2 infection among healthcare workers (HCWs) eligible for vaccination.

This generic protocol for ECDC studies describes the design and methods for a prospective multi-country cohort study of hospital-based healthcare workers (HCWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection.

This pilot protocol is primarily intended to guide the implementation of a first pilot ECDC-funded study using routinely collected data, and includes a concise overview of the systems of the countries included in the pilot study.

This document sets out a number of scenarios that are intended to be plausible, internally consistent, and coherent descriptions of possible futures.

This protocol outlines the methods for a prospective cohort study in long-term care facilities (LTCFs) to evaluate the effectiveness of COVID-19 vaccines in preventing laboratory-confirmed SARS-CoV-2 symptomatic infection in LTCF residents.

This document offers an overview of the available scientific and epidemiological evidence and provides public health considerations to support decisions on the implementation of additional booster doses of COVID-19 vaccine.